查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456938

嗜伊紅性食道炎治療市場－2024年至2029年預測

Eosinophilic Esophagitis Disease Treatment Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年，嗜伊紅性食道炎治療市值為379,961,000美元，複合年成長率為8.12%，到2029年市場規模將達到656,118,000美元。

嗜伊紅性食道炎是一種慢性疾病。胃食道逆流症（GERD）和嗜伊紅性食道炎通用的症狀，例如胸痛和吞嚥困難。多年來，它被認為是一種常見於兒童的疾病，但現在可以登記的年輕人病例數量正在增加。嗜伊紅性食道炎的常見症狀是吞嚥困難、胸腔或上腹部疼痛、嘔吐。

當食道充滿稱為嗜酸性粒細胞細胞的白血球時，就會發生嗜伊紅性食道炎。這些嗜酸性粒細胞應該保留在胃腸道中，但如果它們在其他地方積聚，則會引起器官內的不適和發炎。

嗜伊紅性食道炎II型發炎疾病的盛行率上升、治療方法的進步以及與FDA認證核可藥爭奪先發優勢等因素推動了嗜伊紅性食道炎治療市場的發展，預計該市場將受到激烈競爭的推動。嗜伊紅性食道炎的許多需求支持了嗜伊紅性食道炎藥物產業的蓬勃發展。嗜伊紅性食道炎的診斷標準有缺陷，因為它們依賴專家意見（胃腸病學家、過敏科醫生和病理學家的共識）而不是證據。嗜伊紅性食道炎的組織學標準目前尚不清楚，因為疾病活動性與患者症狀之間沒有相關性，需要反覆組織學檢查才能確認疾病發作。

以下是成人和兒童嗜伊紅性食道炎的症狀。在成人中，症狀包括未消化的食物逆流、咀嚼卡在食道的食物時胸痛以及咀嚼和吞嚥食物困難。在兒童中，一些常見症狀包括吞嚥困難和食物卡在食道中，其他症狀包括嘔吐、腹痛、餵食困難和對藥物反應遲鈍。

市場促進因素：

  • 加強對嗜酸性粒細胞相關疾病的宣導活動將推動市場成長。

正在設計和實施各種教育計劃，以向公眾和醫療相關人員提供有關嗜酸性粒細胞相關疾病的教育，預計這將支持市場擴張。嗜伊紅性食道炎市場是由胃腸道發炎疾病的增加所推動的。過敏、食道內嗜酸性粒細胞積聚、吞嚥困難和食道內嵌塞的增加預計將推動嗜伊紅性食道炎市場的成長。

  • 及時、快速核准的監管支援預計將推動市場成長。

監管支持和快速核准可能會顯著促進嗜伊紅性食道炎疾病治療藥物市場的發展。這些包括更快的藥物開發、更快的市場進入、投資便利、快速通道和突破性治療等指定項目以及臨床試驗設計的彈性。監管機構也特別考慮罕見疾病，簡化監管途徑並鼓勵創新。這些因素促進了 EoE 治療市場的成長，解決未滿足的醫療需求，提供改善生命和挽救生命的治療方法，並促進新治療方法開發的創新。

市場限制因素：

  • 缺乏疾病意識和治療可接受性可能會阻礙市場成長

全球嗜伊紅性食道炎市場可能會因該地區缺乏疾病意識和治療可接受性而受到阻礙。迄今為止，尚未核准針對嗜伊紅性食道炎的特異性治療方法。美國食品藥物管理局（FDA）等監管機構對參與藥物臨床開發、製造、行銷和分銷的組織施加重要且嚴格的限制，使得獲得藥物核准耗時且困難。

北美預計將主導嗜伊紅性食道炎治療藥物市場。

由於對降低氣喘風險的藥物和高階醫療保健的需求不斷增加，預計北美將擁有最大的嗜伊紅性食道炎治療藥物市場規模。由於導致嗜酸性粒細胞細胞疾病的過敏發生率不斷增加，歐洲預計將成為嗜伊紅性食道炎的第二大市場。由於非專利藥廠商的意識和存在不斷增強，亞太地區可能在預測期內佔據嗜伊紅性食道炎市場的最大市場佔有率。

然而，高昂的治療成本和缺乏患者資訊限制了中東、非洲和南美洲等國家的嗜伊紅性食道炎市場。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章嗜伊紅性食道炎治療市場：依產品類型

  • 介紹
  • 仿單標示外藥物
    • 市場機會趨勢
    • 成長前景
    • 地域盈利
  • Budesonide奈德口服懸浮液
    • 市場機會趨勢
    • 成長前景
    • 地理收益
  • FluticasoneODT
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 美泊利單抗
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 瑞利珠單抗
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 貝那利珠單抗
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 杜皮爾·納布
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • Omalizumab
    • 市場機會和趨勢
    • 成長前景
    • 地理收益

第6章嗜伊紅性食道炎治療市場：依通路分類

  • 介紹
  • 醫院藥房
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 零售藥房
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 網路藥房
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利

第7章嗜伊紅性食道炎治療市場：依地區

  • 介紹
  • 北美洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 南美洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 歐洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 中東/非洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 亞太地區
    • 依產品類型
    • 按分銷管道
    • 按國家/地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Ellodi Pharmaceuticals
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Plc
  • Sanof
  • Takeda Pharmaceutical Company Limited
  • Pfizer
簡介目錄
Product Code: KSI061612287

The eosinophilic esophagitis disease treatment market is evaluated at US$379.961 million for the year 2022 growing at a CAGR of 8.12% reaching the market size of US$656.118 million by the year 2029.

EoE (Eosinophilic esophagitis) is a disease of chronic type. Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis share symptoms such as chest pain and difficulty swallowing. It was considered a common disease in children for many years but has now grown in cases in young people that can be registered. Common symptoms of EOE are difficulty swallowing, pain in the chest cavity and upper abdomen, and vomiting.

The condition of eosinophilic Esophagitis occurs when the esophagus is filled with white blood cells, which are also known as eosinophils. These eosinophils should remain inside the digestive tract if they build up elsewhere, creating discomfort and inflammation inside the organ.

The market for eosinophilic esophagitis disease treatment is expected to be pushed by the rising prevalence of type II inflammatory illnesses, such as EoE, advancements in treatment approaches, and fierce competition among competitors for the first FDA-approved medicine to gain a first-mover advantage. EoE has a lot of needs, which is helping the eosinophilic esophagitis medication sector flourish. EoE diagnosis criteria are flawed since they are reliant on professional opinions (agreement among gastroenterologists, allergists, and pathologists) rather than evidence. Because there is no correlation between disease activity and patient symptoms, histologic criteria for EoE are currently unclear, and repeated tissue testing is required to confirm disease initiation.

The following are the symptoms of Eosinophilic Esophagitis in adults and children: In adults, symptoms are the backflow of undigested food, chest pain while chewing food that gets stuck in the esophagus, and difficulty in chewing and swallowing the food. In a child, some symptoms are common, like difficulty swallowing, and food getting stuck in the esophagus, while other symptoms in the child are vomiting, abdominal pain, difficulty eating, and no response to the medication.

MARKET DRIVER:

  • Increasing awareness campaigns for eosinophil-associated illnesses will bolster the growth of the market.

Various public and medical awareness programs have been designed and implemented to educate the public and medical community about eosinophil-related illnesses, which is expected to fuel market expansion. The market for eosinophilic esophagitis is being driven by an increase in the occurrences of digestive tract inflammatory illnesses. Eosinophilic esophagitis (EoE) market growth is expected to be boosted by increased allergies in the esophagus, eosinophil build-up, dysphagia, and impaction in the esophagus.

  • Regulatory support with timely and expedited approvals is expected to surge the market growth.

Regulatory support and expedited approvals can significantly boost the Eosinophilic Esophagitis (EoE) disease treatment market. This includes faster drug development, faster market access, encouraging investment, designation programs like Fast Track and Breakthrough Therapy, and flexibility in clinical trial design. Regulatory agencies also provide special considerations for rare diseases, streamline regulatory pathways, and encourage innovation. These factors contribute to the growth of the EoE treatment market, addressing unmet medical needs, providing life-improving or life-saving treatments, and fostering innovation in the development of novel treatment modalities.

MARKET RESTRAINTS:

  • Lack of disease awareness and treatment acceptability could hamper the market growth

The global eosinophilic esophagitis (EoE) market may be hampered by a lack of disease awareness and the acceptability of treatment for a given location. For the time being, no specific treatment for eosinophilic esophagitis has been approved. Obtaining regulatory approval for the drug is time-consuming and difficult, as regulatory agencies such as the US Food and Drug Administration (FDA) place significant and stringent restrictions on organizations involved in the clinical development, manufacture, marketing, and distribution of drugs.

North America is expected to dominate the Eosinophilic Esophagitis Treatment Market.

With the rising demand for asthma risk-reducing medications and high-end medical treatments, it is predicted that North America will have the biggest market volume in the Eosinophilic Esophagitis Treatment Market. Because of the increased occurrence of allergies that cause eosinophilic illnesses, Europe is expected to be the second-largest market for eosinophilic esophagitis (EoE). Due to growing awareness and the existence of generic companies, Asia-Pacific is likely to account for the biggest market share in the eosinophilic esophagitis (EoE) market in the forecasted period.

However, in places such as the Middle East, Africa, and South America, high therapeutic costs and a lack of patient information are limiting the eosinophilic esophagitis market.

Key development

  • September 2023- The FDA has approved Dupixent(R) (dupilumab) for Priority Review to treat children aged 1-11 with eosinophilic esophagitis (EoE). Dupixent is the first and only treatment in the U.S. approved for children and adults aged 12 and older with EoE, weighing at least 40kg. If approved, it would be the first and only treatment indicated in the U.S. for children aged 1-11.
  • May 2022- The FDA has approved Dupixent (dupilumab) as the first treatment for Eosinophilic Esophagitis (EoE), a chronic immune disorder affecting adults and pediatric patients aged 12 and above. EoE is a chronic inflammatory disorder characterized by difficulty swallowing, eating, and food sticking in the esophagus. Dupixent is a monoclonal antibody that inhibits part of the inflammatory pathway, making it the first FDA approval for a treatment for EoE.

Segmentation

By Product Type

  • Off-Label Drugs
  • Budesonide Oral Suspension
  • Fluticasone ODT
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • Dupilunab
  • Omalizumab

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Off-Label Drugs
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Budesonide Oral Suspension
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Fluticasone ODT
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Mepolizumab
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Reslizumab
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness
  • 5.7. Benralizumab
    • 5.7.1. Market Opportunities and Trends
    • 5.7.2. Growth Prospects
    • 5.7.3. Geographic Lucrativeness
  • 5.8. Dupilunab
    • 5.8.1. Market Opportunities and Trends
    • 5.8.2. Growth Prospects
    • 5.8.3. Geographic Lucrativeness
  • 5.9. Omalizumab
    • 5.9.1. Market Opportunities and Trends
    • 5.9.2. Growth Prospects
    • 5.9.3. Geographic Lucrativeness

6. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Hospital Pharmacies
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Retail Pharmacies
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Online Pharmacies
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Product Type
    • 7.3.2. By Distribution Channel
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Product Type
    • 7.4.2. By Distribution Channel
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. United Kingdom
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Spain
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Others
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Product Type
    • 7.5.2. By Distribution Channel
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Product Type
    • 7.6.2. By Distribution Channel
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Indonesia
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Others
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Ellodi Pharmaceuticals
  • 9.2. AstraZeneca Plc
  • 9.3. Bristol-Myers Squibb Co
  • 9.4. GlaxoSmithKline Plc
  • 9.5. Sanof
  • 9.6. Takeda Pharmaceutical Company Limited
  • 9.7. Pfizer